Technical Analysis for CRL - Charles River Laboratories International, Inc.

Grade Last Price % Change Price Change
grade C 129.4 -0.49% -0.64
CRL closed up 1.02 percent on Tuesday, May 21, 2019, on 64 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Down Down
See historical CRL trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -0.49%
Crossed Above 200 DMA Bullish -0.49%
Narrow Range Bar Range Contraction -0.49%
NR7 Range Contraction -0.49%
Multiple of Ten Bullish Other -0.49%
Gapped Up Strength -0.49%
Oversold Stochastic Weakness -0.49%
200 DMA Resistance Bearish 0.52%
Lower Bollinger Band Touch Weakness 0.52%
Oversold Stochastic Weakness 0.52%

Older signals for CRL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment is involved in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, research animal diagnostic services, endotoxin and microbial detection products and services, and avian vaccine products and services. The PCS segment provides preclinical services, including both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Biotechnology Life Sciences Pharmaceutical Pharmaceutical Industry Drug Discovery Program Management Pharmacokinetics Contract Research Organizations Drug Metabolism Pre Clinical Development
Is CRL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 149.065
52 Week Low 103.0
Average Volume 359,132
200-Day Moving Average 129.5761
50-Day Moving Average 140.0088
20-Day Moving Average 136.1345
10-Day Moving Average 132.397
Average True Range 3.6522
ADX 32.12
+DI 14.5879
-DI 32.9456
Chandelier Exit (Long, 3 ATRs ) 133.3034
Chandelier Exit (Short, 3 ATRs ) 138.2216
Upper Bollinger Band 145.4766
Lower Bollinger Band 126.7924
Percent B (%b) 0.17
BandWidth 13.724809
MACD Line -2.8718
MACD Signal Line -2.1313
MACD Histogram -0.7405
Fundamentals Value
Market Cap 6.19 Billion
Num Shares 47.6 Million
EPS 3.80
Price-to-Earnings (P/E) Ratio 34.22
Price-to-Sales 3.11
Price-to-Book 5.83
PEG Ratio 2.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 132.25
Resistance 3 (R3) 132.47 131.97 131.88
Resistance 2 (R2) 131.97 131.41 131.85 131.75
Resistance 1 (R1) 131.00 131.06 131.49 130.78 131.63
Pivot Point 130.50 130.50 130.74 130.38 130.50
Support 1 (S1) 129.53 129.94 130.02 129.31 128.45
Support 2 (S2) 129.03 129.59 128.91 128.33
Support 3 (S3) 128.06 129.03 128.20
Support 4 (S4) 127.84